FX.co ★ Crown Laboratories, Revance Amend A&R Merger Agreement; Increases Offer Price To $3.65/shr

Crown Laboratories and Revance Therapeutics (RVNC) have disclosed an amendment to their previously established Amended and Restated Merger Agreement, effective January 17, 2025. Under this revised agreement, Revance shareholders are set to receive $3.65 per share of common stock, with a par value of $0.001 per share, paid in cash. This payment will be made without interest but will account for any applicable tax deductions. This amended offer represents an increase of $0.55, or 17% per share, from the previous proposal. Consequently, Crown will prolong its current tender offer for all outstanding shares of Revance until one minute after 11:59 p.m. Eastern Time on February 4, 2025.